3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
5
Neoplasm Metastasis
4
Breast Neoplasms
4
Lung Neoplasms
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Glioblastoma
2
Urinary Bladder Neoplasms
1
Stroke
1
Stress Disorders, Post-Traumatic
1
Recurrence
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neurologic Manifestations
1
Myelodysplastic Syndromes
1
Motor Activity
1
Melanoma
1
Margins of Excision
1
Malignant Solid Neoplasm
1
Malignant Female Reproductive System Neoplasm
1
Localized Head and Neck Carcinoma
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Inflammatory Breast Neoplasms
1
Hematologic Neoplasms
1
Fallopian Tube Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
8
Specimen Handling
5
Nivolumab
5
selpercatinib
4
Iodine-124
4
Biopsy
4
pembrolizumab
3
binimetinib
3
Iodine-131
3
Cetuximab
3
ulixertinib
2
trametinib
2
omipalisib
2
lenvatinib
2
larotrectinib
2
durvalumab
2
defactinib
2
dabrafenib
2
Surveys and Questionnaires
2
Sunitinib
2
Radiosurgery
2
Ipilimumab
2
Immunoglobulin G
2
Gemcitabine
2
Disulfides
2
Cyclophosphamide
2
CTLA-4 Antigen
2
tremelimumab
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
Palliative Care
×
90 days
×
Clear all
No trials found.